The PTEN conundrum: how to target PTEN-deficient prostate cancer

DJ Turnham, N Bullock, MS Dass, JN Staffurth… - Cells, 2020 - mdpi.com
Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome
10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to …

[HTML][HTML] Molecular pathways and targets in prostate cancer

E Shtivelman, TM Beer, CP Evans - Oncotarget, 2014 - ncbi.nlm.nih.gov
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression.
The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous …

Novel tools for prostate cancer prognosis, diagnosis, and follow‐up

A Dimakakos, A Armakolas… - BioMed research …, 2014 - Wiley Online Library
Prostate‐specific antigen (PSA) is the main diagnostic tool when it comes to prostate cancer
but it possesses serious limitations. Therefore, there is an urgent need for more sensitive …

[HTML][HTML] Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical …

K Lahdensuo, A Erickson, I Saarinen, H Seikkula… - Modern Pathology, 2016 - Elsevier
The clinical course of prostate cancer is highly variable. Current prognostic variables, stage,
and Gleason score have limitations in assessing treatment regimens for individual patients …

[HTML][HTML] Androgen receptors beyond prostate cancer: an old marker as a new target

J Munoz, JJ Wheler, R Kurzrock - Oncotarget, 2015 - ncbi.nlm.nih.gov
Androgen receptors (ARs) play a critical role in the development of prostate cancer.
Targeting ARs results in important salutary effects in this malignancy. Despite mounting …

The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis

R Liu, J Zhou, S Xia, T Li - Clinical and Translational Oncology, 2020 - Springer
Background The specific association between PTEN deletion or ERG rearrangement and
the recurrence of prostate cancer (PC) treated with radical prostatectomy (RP) or …

Clinical utility and biologic implications of phosphatase and tensin homolog (PTEN) and ETS-related gene (ERG) in prostate cancer

D Ullman, D Dorn, S Rais-Bahrami, J Gordetsky - Urology, 2018 - Elsevier
Phosphatase and tensin homolog (PTEN) and ETS-related gene (ERG) mutations are
commonly found in prostate cancer. Although mouse studies have demonstrated that PTEN …

Neoadjuvant treatment of high-risk, clinically localized prostate cancer prior to radical prostatectomy

EJ Pietzak, JA Eastham - Current urology reports, 2016 - Springer
Multimodal strategies combining local and systemic therapy offer the greatest chance of cure
for many with men with high-risk prostate cancer who may harbor occult metastatic disease …

The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis

T Gao, Y Mei, H Sun, Z Nie, X Liu, S Wang - Biomedicine & …, 2016 - Elsevier
Objective Phosphatase and tensin homolog (PTEN) deleted on chromosome 10, a tumor
suppressor that negatively regulates the phosphoinositide-3-kinase (PI3 K) which has been …

Correlations of PTEN and ERG immunoexpression in prostate carcinoma and lesions related to its natural history: Clinical perspectives

O Voulgari, D Goutas, A Pergaris… - Current Issues in …, 2023 - mdpi.com
Purpose: The aim of our study was to observe the associations between the ETS-related
gene (ERG) and the phosphatase and tensin homolog gene (PTEN) immunoexpression in …